Business Wire

Planforge Introduces Product Maturity Level Tracking with New Gate Management Option

13.2.2025 14:30:00 CET | Business Wire | Press release

Share

Release 25 Also Introduces First GenAI-Powered Assistant Features and Configurable Portfolio Dashboards

Planforge today announced Planforge 25, the latest release of its industry-leading project work management software. The new version introduces the Gate Management Option (GMO), an optional module developed specifically to help track the product maturity level for development projects. With version 25, Planforge also ships their first GenAI-powered assistant features as announced late last year. The release also features more configurable portfolio dashboards.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250213182628/en/

Planforge 25: New Gate Management Option enables seamless product maturity tracking in development projects. (Graphic: Business Wire)

Gate Management for Development Projects

With its new Gate Management Option, Planforge builds a bridge between development processes and projects by directly integrating support for process gates into project planning. A process gate is a key decision point in a workflow where progress is evaluated to ensure criteria are met before moving to the next phase. Gates are uniquely defined on the project pipeline stage level, and can then be used in project templates and plans together with progress criteria and due dates.

Process gate criteria are based on work packages (WP) and target progress levels per WP. Therefore, the maturity level per criterion can be automatically derived based on actual WP progress. Process gate maturity levels are in turn aggregated based on criteria progress levels. Also target dates for process gates can be automatically monitored based on actual versus planned finish dates of their linked work packages.

"In the technology and automotive industries, gate management today involves a lot of manual work, as project plans are not integrated with process gates in any way," said Gerald Aquila, founder & CEO of Planforge. "With Planforge 25, we are changing the game: by directly reusing existing actual project management data for monitoring and controlling process gates we can not only save many hours of work, but also cut administrative costs significantly."

Additionally, Planforge now integrates a simple but powerful gate review process where go/no-go decisions, gate revisions, and required measures can be easily tracked in a revision-safe way. This allows for early warnings and delivers more transparency and more insightful KPIs. All gate-related information is clearly summarised in dedicated new views for gates planning and controlling, covering single and multiple projects alike.

First Assistant Features of GenAI Initiative

Planforge 25 further introduces the first assistant features of the company’s broader GenAI initiative. For instance, project managers can ask the system for suggestions for SMART (specific, measurable, achievable, realistic and time-bound) project objectives based on the current project description and additional related meta data such as linked ideas. These functions are context-sensitive, directly embedded in the main user interface (in this case, the project charter) and currently powered by OpenAI's ChatGPT.

Configurable Portfolio Dashboards

After introducing custom KPIs and configurable KPI overviews last year, Planforge 25 now also makes portfolio dashboards configurable. Just like for the KPIs view, users can now easily configure the displayed widgets via drag and drop per portfolio.

Availability

Planforge is free for up to four users. Larger teams can test the project work management software via a free 30-day trial. For more information or to be among the first to try the new Gate Management Option, please contact the Planforge sales team at info@planforge.io.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250213182628/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye